Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Characteristics And Treatment Outcomes In 132 Patients With Malignant Mesothelioma

A. Abakay, A. C. Tanrıkulu, M. Kaplan, M. Kuçukoner, O. Abakay, H. Şen, A. Işıkdoğan, A. Şenyiğit
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: Our objective is to scrutinize clinical, laboratory, radiological characteristics, treatment regimens, and treatment outcomes of malignant mesothelioma (MM) cases in our hospital. Materials and Methods: We investigated, retrospectively, the clinical characteristics and treatment outcomes of all 132 MM patients at Dicle University Hospital between January 2006 and April 2010. Results: A total of 82 (62.1%) patients were male, and 50 (37.9%) female. Median age was 56.0 years. Mean survival time was 9.6±6.9 months. Mean survival time of patients who had received best supportive care was 7.5 months, chemotherapy 10.4 months, and multimodality treatment regimen 12.6 months. Patients in the multimodality treatment group survived longer than did those in the other two groups (P=0.042). A total of 76 patients received chemotherapy, of whom 17 (22.3%) were administered Cisplatin/Carboplatin and Gemcitabine, 58 (76.4%) Cisplatin/Carboplatin and Pemetrexed, and one (1.3%) Cisplatin + Docetaxel. Complete and partial response to treatment in patients receiving Cisplatin/Carboplatin and Gemcitabine was found 47.1% and Cisplatin/Carboplatin and Pemetrexed was found 50.0% (P>0.05). Conclusions: MM related to asbestos exposure is seen frequently in Turkey. Patients present with the typical clinical features of dyspnea, weight loss, and chest pain. Survival analysis shows that patients receiving multimodality treatment may be better.
This paper references
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
Abakay, et al.: Clinical characteristics of mesothelioma Lung India
P Borasio (2011)
10.1136/thx.45.9.649
Role of asbestos and other fibres in the development of diffuse malignant mesothelioma.
A. Gibbs (1990)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1378/CHEST.102.3.790
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
10.1016/S1077-9108(08)79041-8
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
10.1016/S0954-6111(99)90318-9
Environmental asbestos exposure and malignant pleural mesothelioma.
M. Metintas (1999)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
Single center experience of mesothelioma patients in southeast region of Turkey
T Cil (2009)
10.1136/thx.35.8.564
Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust.
S. Yazicioglu (1980)
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey : CT Findings in 117 Patients
H. Leblebı̇cı̇a (2000)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
Environmental malignant pleural mesothelioma in Southeast Turkey.
A. C. Tanrıkulu (2006)
10.1007/BF01600160
The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma
T. Gelder (2005)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
The pathogenesis of malignant and nonmalignant serosal lesions in body cavities consequent to asbestos exposure
J. Craighead (1994)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1097/JTO.0b013e3181ba2033
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Guntulu Ak (2009)
10.1136/oem.56.8.505
Mesothelioma: cases associated with non-occupational and low dose exposures.
G. Hillerdal (1999)
Malignant pleural mesothelioma due to environ mental mineral fiber exposure in Turkey
ZT Selçuk (1992)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1378/CHEST.107.6_SUPPLEMENT.332S
Current approach to malignant mesothelioma of the pleura.
J. Aisner (1995)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.1097/CPM.0b013e318235181f
Asbestos-related Lung Disease: An Update
M. Schuhmann (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar